All In Biotech

Drug Trial Radar · NCT04839016

Efficacy 、Safety and PK of SHR-1314 in Patients With Moderate-to-Severe Plaque Psoriasis

A Randomized, Double-blind, Multicenter, Placebo-controlled, Phase III Adaptive Study of SHR-1314 to Assess Efficacy and Safety in Patients With Moderate-to-Severe Plaque Psoriasis

Last checked: Nov 19, 2026Latest source record: Apr 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 660 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

660

Planned (sponsor's estimate)

Start

Apr 25, 2021

Primary completion

Aug 30, 2023

Study completion Aug 30, 2023

Sponsor

Sponsor type
Industry
First posted
Apr 9, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess efficacy, safety, pharmacokinetics and immunogenicity of subcutaneous SHR-1314 in Patients with Moderate-to-Severe Plaque Psoriasis

Conditions

  • Moderate-to-Severe Plaque Psoriasis

Interventions

  • SHR-1314Drug

    SHR-1314

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of subjects who achieve at least 90% improvement in PASI score (PASI 90) at Week 12Time frame: Week 12
  2. sPGA of 0 or 1 response at Week 12Time frame: Week 12

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.